Key Takeaways: China Feihe posted declines in both profits and sales last year, as it is heavily exposed to the country’s falling birth rate The company, which gets 91% of its revenue from infant milk formula, may remain attractive to investors due to its pledge to pay much of its profits as dividends By Edith Terry
China’s restrictions on overseas access to data are driving investors away, according to short seller Blue Orca Capital LLC, whose founder says the curbs undermine the investment case for the world’s second-largest stock market.
(Bloomberg) China’s restrictions on overseas access to data are driving investors away, according to short seller Blue Orca Capital LLC, whose founder says the curbs undermine the investment case for the world’s second-largest stock market.Most Read from BloombergHundreds Dead at Gaza Hospital as Israel, Hamas Trade BlameIsrael Latest: Biden to Visit as Oil Climbs After Hospital BlastTreasury Yields Climb as Hot Data Fuel Fed Wagers: Markets WrapWill Xi Jinping’s Gamble on Vladimir Putin Pay
Makers of infant formula use misleading marketing and aggressive lobbying tactics to drive sales in a $55 billion-a-year industry, according to a three-paper series from the World Health Organisation.